Calistoga Pharmaceuticals Appoints Andrew Guggenhime as CFO
Calistoga Pharmaceuticals, a developer of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, has appointed Andrew Guggenhime as chief financial officer (CFO). A veteran financial executive, Guggenhime has spent the last 10 years as CFO for leading public companies, including biotechnology companies Facet Biotech Corporation and PDL BioPharma. Prior to his public company roles, Guggenhime served in the investment and corporate banking businesses.
Guggenhime joins Calistoga from Facet Biotech, an emerging biotechnology company that was focused on the development of novel therapeutics, where he served as senior vice president (SVP) and CFO. Facet Biotech was acquired by Abbott Laboratories in April 2010. Guggenhime served as SVP and CFO of PDL BioPharma from April 2006 until Facet Biotech was spun off from PDL BioPharma in December 2008. During his tenure at Facet and PDL, he was responsible for the finance, investor relations, programme management, information technology and corporate services organisations.
Prior to joining Facet, Guggenhime served as CFO for Neoforma, a provider of supply chain management solutions for the healthcare industry before it was acquired by Global Healthcare Exchange in March 2006. Prior to joining Neoforma, he was a vice president in the Healthcare Investment Banking group of Merrill Lynch & Co, where he specialised in working with healthcare companies on a variety of transactions, including mergers and acquisitions (M&As), initial public offerings (IPOs), add-on equity offerings and debt offerings. Prior to that, he worked at Wells Fargo & Company.
Guggenhime received his BA in International Politics and Economics from Middlebury College and his MM from the JL Kellogg Graduate School of Management at Northwestern University.